Entecavir Antiviral Treatment For HBV Related HCC Root For The Influence Of Clinical Outcome After Ablation

Objective:To study the entecavir antiviral therapy for hepatitis B virus related liver cell carcinoma radical ablation effect for the treatment of the postoperative clinical outcome.Methods:A retrospective study of tianjin since the second people's hospital between January2011 and February 2014,admitted during the period of 103 cases of hepatitis B virus associated with HCC,will be divided into two groups according to the antiviral treatment in patients with drugs,the radical ablation in combination with lamivudine antiviral treatment group(n = 50)and radical ablation in combination with entecavir antiviral treatment group(n = 53),application of antiviral treatment were followed up for 3 years after ablation,observe the before and during treatment of ALT,AST,GGT,ALB,TBIL,BUN and CRE,PLT,PT,HBs Ag,HBe Ag,high sensitivity HBV-DNA,the change of AFP,observation period of tumor recurrence of freshman/situation,follow-up of patients with complications during treatment,follow-up of patients survival period,to assess the entecavir antiviral therapy for hepatitis B virus associated surial and quality of life for patients with hepatocellular carcinoma clinical outcome and effect.Results:1.Two groups of patients before treatment in ALT,AST,GGT,ALB,TBIL,BUN and CRE,PLT,PT,HBs Ag,HBe Ag,high sensitivity HBV-DNA,AFP,BCLC stage and tumor differentiation degree had no significant difference(P > 0.05).2.For the treatment of two groups of patients before treatment,1 month,3 months,6months,1 year,2 years and 3 years of ALT,AST,GGT,ALB,TBIL,BUN and CRE,PLT,PT,HBs Ag,HBe Ag,the indicators are no significant difference(P > 0.05).3.Analysis of two groups all the time high sensitivity HBV-DNA level,the two groups in antiviral treatment 1 month,3 months and 6 months high sensitivity HBV-DNA levels,after statistics processing insignificant(P > 0.05),treatment for 1year,2 years and 3 years high sensitivity HBV-DNA level in both groups,after statistics processing significant(P = 0.016,P = 0.016,P = 0.012).4.For the treatment of two groups of patients before treatment,1 month,3 months,6months,1 year,2 years and 3 years liver function Child-Pugh score were compared,the results show two groups of patients before treatment,treatment 1 month,3 months,6 months liver function Child-Pugh score was no significant difference(P > 0.05),the antiviral treatment after 1 year,Child-Pugh score compared two groups of patients had significant difference(P = 0.03,P = 0.03,P = 0.021).5.Two groups of patients in the treatment of 1 month,3 months,6 months,1 year,2years and 3 years tumor recurrence of freshman/during the study,two groups of patients with antiviral treatment 1 month,3 months,6 months during tumor recurrence of freshman/situation is no significant difference(P>0.05),antiviral treatment 1 year,2 years and 3 years,two groups of patients with tumor recurrence of freshman/situation,all have significant difference(P = 0.024,P = 0.024,P = 0.019).6.Patients with follow-up of two groups of treatment complications occurred during the study,two groups of patients in the upper gastrointestinal bleeding and liver nodules rupture bleeding complications occurred more,there are significant differences(P<0.05).And in other complications situation is,there was no significant difference(P > 0.05).7.All landowners were two groups of patients survival,two groups of patients with antiviral treatment for 6 months,1 year,2 year survival rate comparison,there was no significant difference(P > 0.05),patients with antiviral treatment for 3 years survival rate comparison,there are significant differences(P < 0.05).Conclusion:For the hepatitis B virus associated radical ablation of postoperative patients with hepatocellular carcinoma and entecavir antiviral treatment can restrain the HBV replication to the lower level,improve liver function,reduce the events of the end-stage liver disease,improve the quality of life,reduce the recurrence of tumor/new risk,a higher survival rate.